2-(cyclooct-2-ynyloxy)ethanamine | 1194977-75-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(cyclooct-2-ynyloxy)ethanamine
• 英文别名: 2-Cyclooct-2-yn-1-yloxyethanamine；2-cyclooct-2-yn-1-yloxyethanamine
• CAS: 1194977-75-7
• 化学式: C₁₀H₁₇NO
• 分子量: 167.251
• InChiKey: JDTBJSKHZPJGOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(cyclooct-2-ynyloxy)ethanamine 、 5'-deoxy-5'-N-methyl-N'-(4-butyric acid)-2',3'-O,O-(1-methylethylidene)adenosine 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 以94%的产率得到5'-deoxy-5'-N-methyl-N'-{4-[2-(cyclooct-2-ynyloxy)ethanamine] butyramide}-2',3'-O,O-(1-methylethylidene)adenosine
  参考文献：
  名称：

  Identification of stable S-adenosylmethionine (SAM) analogues derivatised with bioorthogonal tags: effect of ligands on the affinity of the E. colimethionine repressor, MetJ, for its operator DNA

  摘要：

  本文介绍了一系列稳定的 SAM 拟态物质的高效合成及其促进大肠杆菌蛋氨酸抑制因子 (MetJ) 与其操作 DNA 结合的能力。

  DOI：

  10.1039/b816495a
• 作为产物：
  描述：

  (Z)-2-(2-bromocyclooct-2-enyloxy)ethanamine 在 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 以85%的产率得到2-(cyclooct-2-ynyloxy)ethanamine
  参考文献：
  名称：

  Identification of stable S-adenosylmethionine (SAM) analogues derivatised with bioorthogonal tags: effect of ligands on the affinity of the E. colimethionine repressor, MetJ, for its operator DNA

  摘要：

  本文介绍了一系列稳定的 SAM 拟态物质的高效合成及其促进大肠杆菌蛋氨酸抑制因子 (MetJ) 与其操作 DNA 结合的能力。

  DOI：

  10.1039/b816495a

文献信息

• [EN] METHODS OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GROWTH DIFFERENTIATION FACTOR 15 (GDF-15)<br/>[FR] MÉTHODES DE TRAITEMENT OU D'AMÉLIORATION DE TROUBLES MÉTABOLIQUES À L'AIDE DU FACTEUR-15 DE CROISSANCE ET DE DIFFÉRENCIATION (GDF-15)
  申请人：NOVARTIS AG

  公开号：WO2017109706A1

  公开（公告）日：2017-06-29

  The disclosure relates to the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as end-stage liver disease, hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, liver cirrhosis, primary biliary cirrhosis (PBC), and hepatocellular carcinoma (HCC), by administering to a subject in need a GDF15 protein or a functional variant, mutation, fusion, or conjugate thereof, and to pharmaceutical compositions that contain the same.

  该披露涉及通过向需要的受试者施用GDF15蛋白或其功能变体、突变体、融合物或结合物，以及含有相同成分的药物组合物，治疗非酒精性脂肪肝病（NAFLD）和非酒精性脂肪性肝炎（NASH），以及晚期肝病、肝脂肪变性（脂肪肝）、肝纤维化、肝炎、肝硬化、原发性胆汁性肝硬化（PBC）和肝细胞癌（HCC）。
• NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES
  申请人：BARNES David Weninger

  公开号：US20160030585A1

  公开（公告）日：2016-02-04

  The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R 1 , R 2 , R 3 , R 4 , Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种共轭物，其包括通过连接剂与脂肪酸连接的生物分子，其中所述的脂肪酸具有以下的化学式A1、A2或A3：其中，R1、R2、R3、R4、Ak、n、m和p在此定义。本发明还涉及一种制造GDF15共轭物等本发明共轭物的方法，以及其治疗用途，如治疗或预防代谢性疾病或疾病、2型糖尿病、肥胖症、胰腺炎、血脂异常、酒精性和非酒精性脂肪肝病/脂肪性肝炎和其他进行性肝脏疾病、胰岛素抵抗、高胰岛素血症、葡萄糖不耐受、高血糖、代谢综合征、高血压、心血管疾病、动脉粥样硬化、周围动脉疾病、中风、心力衰竭、冠心病、糖尿病并发症（包括但不限于慢性肾脏疾病）、神经病变、胃轻瘫和其他代谢性疾病。本发明还提供了药理活性剂的组合和制药组合物。
• FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES
  申请人：Novartis AG

  公开号：EP3157571B1

  公开（公告）日：2021-11-24
• METHODS OF TREATING ANOREXIA
  申请人：JONES DAVENPORT Juli Erin

  公开号：US20170119851A1

  公开（公告）日：2017-05-04

  The invention relates to the stimulation of appetite and treatment of such appetite-suppressed conditions as cachexia, and in particular to an intranasal route of administration for appetite-stimulating agents such as peptide compounds and fragments related to or comprising the Agouti-Related Peptide (AgRP).
• [EN] METHODS OF TREATING ANOREXIA<br/>[FR] MÉTHODES DE TRAITEMENT DE L'ANOREXIE
  申请人：NOVARTIS AG

  公开号：WO2015179415A1

  公开（公告）日：2015-11-26

  The invention relates to the stimulation of appetite and treatment of such appetite-suppressed conditions as cachexia, and in particular to an intranasal route of administration for appetite-stimulating agents such as peptide compounds and fragments related to or comprising the Agouti-Related Peptide (AgRP).